ParkinsonCanadaV1, Main, Exploration, bibRecord, 004549

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

Identifieur interne : 004549 ( Main/Exploration ); précédent : 004548; suivant : 004550

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

Auteurs : James W. Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada]

Source :

Annals of Neurology [ 0364-5134 ] ; 1992-12.

RBID : ISTEX:646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7

English descriptors

KwdEn :
- Humans, Models, Statistical, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Selegiline (therapeutic use), Survival Analysis.
MESH :
- chemical , therapeutic use : Selegiline.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Humans, Models, Statistical, Survival Analysis.

Abstract

We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.

Url:

https://api-v5.istex.fr/document/646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7/fulltext/pdf

DOI: 10.1002/ana.410320614

Affiliations:

Canada

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic</title>
<author><name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7</idno>
<date when="1992" year="1992">1992</date>
<idno type="doi">10.1002/ana.410320614</idno>
<idno type="url">https://api-v5.istex.fr/document/646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000264</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000264</idno>
<idno type="wicri:Area/Istex/Curation">000264</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D97</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D97</idno>
<idno type="wicri:doubleKey">0364-5134:1992:Schulzer J:the:antiparkinson:efficacy</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:1471871</idno>
<idno type="wicri:Area/PubMed/Corpus">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A43</idno>
<idno type="wicri:Area/PubMed/Curation">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A43</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A43</idno>
<idno type="wicri:Area/Ncbi/Merge">000387</idno>
<idno type="wicri:Area/Ncbi/Curation">000387</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000387</idno>
<idno type="wicri:doubleKey">0364-5134:1992:Schulzer M:the:antiparkinson:efficacy</idno>
<idno type="wicri:Area/Main/Merge">004D99</idno>
<idno type="wicri:Area/Main/Curation">004549</idno>
<idno type="wicri:Area/Main/Exploration">004549</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic</title>
<author><name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, 2211 Wesbrook Mall, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Neurology</title>
<title level="j" type="abbrev">Ann Neurol.</title>
<idno type="ISSN">0364-5134</idno>
<idno type="eISSN">1531-8249</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1992-12">1992-12</date>
<biblScope unit="volume">32</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="795">795</biblScope>
<biblScope unit="page" to="798">798</biblScope>
</imprint>
<idno type="ISSN">0364-5134</idno>
</series>
<idno type="istex">646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7</idno>
<idno type="DOI">10.1002/ana.410320614</idno>
<idno type="ArticleID">ANA410320614</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term>
<term>Models, Statistical</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Selegiline (therapeutic use)</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Models, Statistical</term>
<term>Survival Analysis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
</noRegion>
<name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
<name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004549 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004549 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7
   |texte=   The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.